StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Nice!

<< Previous

Bullboard Posts

Next >>

Post by LithLoveron Aug 18, 2022 5:19pm

240 Views

Post# 34905917

Nice!

They have just shown they don't need much financing and are well aware they dont need to dilute.

" the Company has pursued a flexible financing strategy, including short term loans from insiders, investment banks, and this convertible debenture offering, to meet its cash flow needs while its products acquire traction in the marketplace, all with a view to minimizing dilution for the Company's shareholders," commented James Howard-Tripp, Chairman and CEO of StageZero Life Sciences"

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading